DailyStocks Stock Article Search

https://www.fool.com/investing/2024/04/26/why-abbvie-stock-stumbled-today-despite-the-earnin/?source=iedfolrf0000001 Apr 26, 2024 - Investors are struggling to see past the end of Humira's dominance. 0

https://www.fool.com/earnings/call-transcripts/2024/04/26/abbvie-abbv-q1-2024-earnings-call-transcript/?source=iedfolrf0000001 Apr 26, 2024 - ABBV earnings call for the period ending March 31, 2024. 0

https://www.zacks.com/stock/news/2263588/abbvie-abbv-beats-on-q1-earnings-sales-ups-24-eps-view?cid=CS-ZC-FT-analyst_blog|earnings_article-2263588 Apr 26, 2024 - AbbVie's (ABBV) first-quarter earnings and sales beat estimates. Management hikes the EPS guidance on the back of encouraging Skyrizi product sales. 0

https://www.zacks.com/stock/news/2263401/pce-in-line-to-warmer-pre-market-calms-abbv-beats-xom-misses?cid=CS-ZC-FT-ahead_of_wall_street-2263401 Apr 26, 2024 - Pre-market futures are up across the board: +106 points on the Dow, +45 points on the S&P 500 and +195 on the Nasdaq immediately following this important data's release. 0

https://www.zacks.com/stock/news/2263404/abbvie-abbv-reports-q1-earnings-what-key-metrics-have-to-say?cid=CS-ZC-FT-fundamental_analysis|nfm-2263404 Apr 26, 2024 - While the top- and bottom-line numbers for AbbVie (ABBV) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values. 0

https://www.zacks.com/stock/news/2254098/abbvie-abbv-stock-declines-while-market-improves-some-information-for-investors?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6-2254098 Apr 11, 2024 - The latest trading day saw AbbVie (ABBV) settling at $167.52, representing a -0.89% change from its previous close. 0

https://www.zacks.com/stock/news/2253493/are-you-looking-for-a-high-growth-dividend-stock?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_5-2253493 Apr 10, 2024 - Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? Let's find out. 0

https://www.zacks.com/stock/news/2253351/syros-syrs-up-on-fda-fast-track-tag-for-tamibarotene-in-aml?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2253351 Apr 10, 2024 - The FDA bestows a Fast Track Designation to Syros' (SYRS) pipeline candidate, tamibarotene, in combination with venetoclax and azacitidine to treat newly diagnosed acute myeloid leukemia. Stock rises. 0

https://www.zacks.com/commentary/2252707/top-stock-reports-for-abbvie-salesforce-general-electric?cid=CS-ZC-FT-research_daily-2252707 Apr 09, 2024 - Today's Research Daily features new research reports on 16 major stocks, including AbbVie Inc. (ABBV), Salesforce, Inc. (CRM) and General Electric Company (GE). 0

https://www.zacks.com/stock/news/2251543/aldeyra-aldx-stock-rallies-43-in-one-week-here-s-why?cid=CS-ZC-FT-analyst_blog|price_surge_/_plunge-2251543 Apr 06, 2024 - Aldeyra (ALDX) rises 43% in one week, driven by plans to initiate a pivotal study to support the resubmission of reproxalap NDA for dry eye disease in the first half of 2024. 0